Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Gyre Therapeutics Inc.

Healthcare US GYRE

5.69USD
0.13(2.34%)

Last update at 2026-06-03T20:01:00Z

Day Range

5.505.72
LowHigh

52 Week Range

6.5711.78
LowHigh

Fundamentals

  • Previous Close 5.56
  • Market Cap758.14M
  • Volume72500
  • P/E Ratio393.50
  • Dividend Yield-%
  • EBITDA14.01M
  • Revenue TTM116.59M
  • Revenue Per Share TTM1.30
  • Gross Profit TTM 111.17M
  • Diluted EPS TTM0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 14.44M 23.22M -76.96500M -7.89400M -87.93300M
Minority interest -4.85300M -5.81300M -7.45300M -2.01200M -
Net income 5.03M 12.09M -92.93300M 2.30M -87.93300M
Selling general administrative 20.80M 16.11M 14.66M 17.37M 18.96M
Selling and marketing expenses 65.18M 57.51M 61.16M 54.24M 44.65M
Gross profit 111.17M 101.87M 108.81M -0.00400M -0.04200M
Reconciled depreciation 2.52M 1.59M 1.11M 1.13M 1.93M
Ebit 11.49M 16.23M 114.92M -8.61100M -87.89400M
Ebitda 14.01M 17.82M 116.03M -52.15300M -87.60400M
Depreciation and amortization 2.52M 1.59M 1.11M -43.54200M 0.29M
Non operating income net other - - - - -
Operating income 11.49M 16.16M -67.23000M -8.61100M -87.89400M
Other operating expenses 105.10M 89.59M 94.24M 31.20M 95.23M
Interest expense - - - 0.72M 0.04M
Tax provision 4.56M 5.32M 8.52M 5.10M 6.17M
Interest income 1.75M 1.55M - 4.88M 0.38M
Net interest income 1.75M 1.55M 1.04M 0.73M 0.26M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -4.55600M 5.32M 8.52M 0.35M -0.03900M
Total revenue 116.59M 105.76M 113.45M 0.79M 7.34M
Total operating expenses 99.69M 85.71M 89.60M 30.40M 87.85M
Cost of revenue 5.42M 3.88M 4.64M 0.80M 7.38M
Total other income expense net 2.95M 7.05M -97.22200M 0.72M -0.03900M
Discontinued operations - - - - -
Net income from continuing ops 9.88M 17.90M -85.48000M 4.31M 23.44M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 166.13M 125.41M 116.54M 709.59M 540.87M
Intangible assets 4.73M 1.71M 0.20M 161.25M 132.35M
Earning assets - - - - -
Other current assets 2.83M 2.62M 1.04M - -
Total liab 23.85M 27.00M 102.59M 85.12M 76.04M
Total stockholder equity 106.03M 63.32M -15.82800M 624.47M 464.83M
Deferred long term liab - - - - -
Other current liab 14.57M 15.71M 19.40M - -
Common stock 0.00009M 0.09M 0.08M - -
Capital stock 0.09M 0.09M 0.08M 61.32M 61.32M
Retained earnings -68.42600M -73.45300M -85.53800M 283.04M 147.11M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 37.07M 11.81M 33.51M 163.42M 166.29M
Cash and equivalents - - - - -
Total current liabilities 18.29M 19.52M 20.05M 78.07M 65.63M
Current deferred revenue 0.01M 0.16M 0.08M - -
Net debt -36.13100M -10.21500M -33.10000M - -
Short term debt 0.64M 0.71M 0.21M - -
Short long term debt - - - - -
Short long term debt total 0.94M 1.60M 0.41M - -
Other stockholder equity 172.14M 136.19M 3.65M - -
Property plant equipment - - - - -
Total current assets 102.37M 64.79M 57.22M 333.90M 285.89M
Long term investments 23.52M 24.57M 23.43M 51.50M 0.00000M
Net tangible assets - - - - -
Short term investments 15.36M 14.86M - 10.60M 2.48M
Net receivables 36.95M 29.15M 16.84M 108.75M 64.06M
Long term debt - - - - -
Inventory 10.17M 6.34M 4.28M 42.64M 36.46M
Accounts payable 0.12M 0.11M 0.35M 0.85M 1.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.32M 0.50M 1.45M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 27.43M 3.03M 5.72M - -
Deferred long term asset charges - - - - -
Non current assets total 63.76M 60.62M 59.32M 375.69M 254.98M
Capital lease obligations 0.94M 1.60M 0.41M 4.99M 7.83M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 1.42M -19.88400M -19.76000M -13.81400M -8.19080M
Change to liabilities - - - - -
Total cashflows from investing activities -0.47400M -19.88400M - - -
Net borrowings - - - - -
Total cash from financing activities 24.38M 2.10M 2.50M -45.01100M 49.55M
Change to operating activities - - - - -
Net income 9.88M 17.90M -85.48000M -8.24200M -87.93300M
Change in cash 25.26M -21.69600M 8.33M -22.68100M 13.99M
Begin period cash flow 11.81M 33.51M 25.18M 44.35M 30.36M
End period cash flow 37.07M 11.81M 33.51M 21.67M 44.35M
Total cash from operating activities 1.01M -3.64100M 25.89M -33.09600M -83.75500M
Issuance of capital stock 23.51M 0.77M 2.50M 0.00000M -
Depreciation 2.48M 1.59M 1.11M 0.23M 0.29M
Other cashflows from investing activities 0.69M -0.41200M - - -
Dividends paid - - - 45.03M 0.00000M
Change to inventory -3.63100M -2.13900M 1.75M -0.87900M 3.88M
Change to account receivables -11.95300M -9.28500M 1.40M 1.62M 1.50M
Sale purchase of stock - - - - -
Other cashflows from financing activities -1.48700M 1.33M 2.50M 0.02M 0.30M
Change to netincome - - - - -
Capital expenditures 1.19M 3.13M 8.59M 5.00M 0.84M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -15.55400M -15.68800M 7.46M -4.94500M 0.48M
Stock based compensation 7.16M 0.83M 7.28M 13.37M 3.40M
Other non cash items -1.84500M -7.26800M 96.68M -21.48100M 3.89M
Free cash flow -0.18000M -6.76900M 17.31M -38.09400M -84.59400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GYRE
Gyre Therapeutics Inc.		 0.13 2.34% 5.69 393.50 78.12 6.50 6.84 5.78 48.07
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Gyre Therapeutics Inc.

12770 High Bluff Drive, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Dr. Han Ying Ph.D. CEO & Director NA
Mr. Songjiang Ma President & Director NA
Ms. Ruoyu Chen Interim Chief Financial Officer 1970
Mr. Weiguo Ye Chief Operating Officer NA
Ms. Seline E. Miller CPA Senior Vice President of Finance 1969
Mr. Songjiang Ma President & Director 1956
Ms. Ruoyu Chen Chief Financial Officer 1971
Mr. Weiguo Ye Chief Operating Officer 1978
Dr. Han Ying Ph.D. Senior Vice President of Science 1966
Mr. Ping Zhang Interim CEO & Executive Chair 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.